Salus' technology facilitates the rapid identification of optimal antisense targets on any gene of interest. Antisense drugs are mirror images of small segments of mRNA which may prevent an undesirable protein from being made and thereby treat a disease. Salus was acquired by Genta (NASDAQ: GNTA) in 2003.